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Abstract
The NF-κB (nuclear factor κB) transcription factors control cell survival, proliferation and innate and adaptive
immune response. Post-translational modifications of key components of the NF-κB pathway provide the
molecular basis for signal transmission from the cell membrane to the nucleus. Here, we describe the in-
volvement of different types of ubiquitin modification in the regulation of the NF-κB signalling pathway.
Introduction
The NF-κB (nuclear factor κB) transcription factors are key
regulators of immune response, cell survival and prolifer-
ation, but they also play important roles in development of
human diseases such as cancer development and progression
[1]. NF-κB transcription factors function as a dimer of five
different NF-κB proteins: RelA (p65), RelB, c-Rel, p50 and
p52. All of these proteins possess an RHD (Rel-homology
domain), which is composed of dimerization, nuclear-local-
ization and DNA-binding domains. Under the non-stimul-
ated condition, NF-κB proteins are dimerized and rendered
inactive either by their inhibitor IκB (inhibitory κB), which
holds them in the cytoplasm, or they are kept inactive as
unprocessed, precursor proteins. Cell stimulation activates
IKK (IκB kinase) that phosphorylates IκB, which recruits
the E3 ubiquitin ligase SCF (Skp1/cullin/F-box)–βTrCP
to IκB, resulting in its ubiquitination and proteasomal
degradation. In this way, NF-κB is released and can enter
the nucleus where it regulates the transcription of different
classes of genes, such as cytokines, pro- and anti-apoptotic
genes, growth factors, adhesion molecules, matrix proteases,
cell cycle genes and angiogenic factors [2,3].
Depending on the type of kinase being activated by an
appropriate signal, the NF-κB activation pathway is named
the classical (canonical) pathway, involving mostly IKKβ,
or the alternative (non-canonical) pathway, which is strictly
dependent on IKKα. The classical pathway is the predom-
inant way of activating NF-κB transcription factors and is
usually triggered in response to microbial infection or pro-
inflammatory cytokine stimulation, whereas the alternative
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pathway is induced by some members of the TNFR [TNF
(tumour necrosis factor) receptor] family. The NF-κB sig-
nalling pathway can be activated by many stimuli including
microbes, inflammatory cytokines, stress, necrotic cell pro-
ducts and antigen stimulation [via TCR (T-cell receptor)].
Most of the biological processes affected by NF-κB signalling
play central roles in carcinogenesis, making NF-κB sig-
nalling and its regulation a major target of cancer research [4].
Both the classical and the alternative NF-κB activation
pathways critically depend on ubiquitin signalling [5,6].
Ubiquitin is a small (8 kDa) protein that can be covalently
and reversibly attached to lysine residues of target proteins
in a process called ubiquitination. Initially, ubiquitin is
activated by a ubiquitin-activating enzyme E1 in an ATP-
dependent process followed by its transfer to a ubiquitin-
conjugating enzyme E2. The final step of the ubiquitination
reaction is carried out by the ubiquitin-protein ligase E3,
which attaches ubiquitin to the lysine residue in the target
protein [7]. Ubiquitin modifications of proteins can occur in
multiple forms [8]. In the simplest way, a single ubiquitin
molecule is attached to a single lysine residue in a substrate,
which is defined as mono-ubiquitination. When several single
ubiquitin molecules are attached to several different lysine
residues, the process is called multiple mono-ubiquitination
or multi-ubiquitination. Moreover, ubiquitin can be added to
lysine residues in the ubiquitin molecule itself, thus forming
ubiquitin chains in a process known as polyubiquitination.
Proteins that are polyubiquitinated with Lys48-linked chains
are targeted for proteasomal degradation. Interestingly, ubi-
quitination of many proteins does not mediate their degrada-
tion but rather has functional consequences for the modified
protein. These include changes in their conformation,
subcellular localization or catalytic activity. In addition, the
attachment of ubiquitin can engage them in protein–protein
interactions with effectors containing UBDs (ubiquitin-
binding domains). This leads to the formation of ubiquitin
signalling networks, which translate signals from the cellular
environment into proper biological phenotypes [8]. In ana-
logy to phosphorylation, ubiquitination is also a dynamic
and reversible modification. The rapid removal of ubiquitin
from substrates is catalysed by DUBs (de-ubiquitinating
enzymes).
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Positive regulators of ubiquitin signals
The NF-κB pathway is regulated by diverse ubiquitination
modifications. Some of these reactions have activating
outcomes, whereas the others down-regulate NF-κB
signalling. Following receptor stimulation, TRAFs (TNFR-
associated factors) are among the first molecules to be
engaged in signal transmission (Figure 1). TRAF proteins
are ubiquitin E3 ligases, which have a pivotal role in the
activation of NF-κB signalling pathway via TLRs (Toll-like
receptors), IL-1R [IL-1 (interleukin-1) receptor] and the
TNFR superfamily [9]. For example, TRAF-2 is recruited
to the activated TNFR via the action of the adaptor protein
TRADD (TNFR-associated via death domain) and through
the interaction with RIP (receptor-interacting protein).
TNFα stimulation induces Lys63-linked polyubiquitination
of RIP, which then associates with TNFR as well as
the regulatory protein IKKγ /NEMO (NF-κB essential
modulator), which activates the IKK complex [10].
On the other hand, TRAF-6 is essential for the IKK
activation following stimulation of the IL-1R and TLRs
(Figure 1). Activation of IL-1R or TLR receptors recruits an
adaptor protein, MyD88 (myeloid differentiation factor 88)
to the receptor, which attracts the protein kinases IRAK1 (IL-
1R-associated kinase 1) and IRAK4 to the complex. IRAK1
binds to MyD88 and to TRAF-6, which in turn activates the
IKK complex [11]. However, TRAF-6 does not activate IKK
directly but rather via its two activators TRIKA1 (TRAF-
6-regulated IKK activator 1) and TRIKA2 [9]. TRIKA1
is a ubiquitin-conjugating E2 enzyme complex consisting
of UBC13 (ubiquitin-conjugating enzyme 13) and UEV1A
(ubiquitin E2 variant 1A) proteins. TRIKA1 functions
together with TRAF-6 (an E3 enzyme) to synthesize a Lys63-
polyubiquitin chain on target proteins including TRAF-6
itself, the regulatory protein NEMO and possibly other
proteins. TRIKA2 is a protein complex consisting of TAK1
[TGF-β (transforming growth factor-β)-activated kinase 1],
TAB1 (TAK1-binding protein) and TAB2. Mutations within
the NZF (Nlp14 zinc finger), the UBD of TAB2, abolishes
its ability to activate TAK1 and IKKβ, suggesting that TAB2
binds to ubiquitinated TRAF-6 (already in complex with
activated receptor) prior to activating TAK1 [9]. It seems that
TAB1 protein is not very important for IKK activation since
deletion and silencing studies of this protein did not impair
IKK functions. On the other hand, TAB2 facilitates TRAF-
6 ubiquitination by IL-1 stimulation, which promotes the
assembly of TRAF-6 with the downstream kinase, IKK [12].
In addition, NF-κB transcription factors play an important
function in immune responses towards specific antigens by
TCR (Figure 1). Following the activation, TCR is recruited
to rafts with Bcl-10 and MALT1 (mucosa-associated
lymphoid tissue lymphoma translocation gene 1) proteins
that induce Lys63-linked polyubiquitination of NEMO
(probably by TRAF-6), leading to the activation of IKKs
[13,14]. Some bacterial receptors are located in the cytoplasm;
NOD (nucleotide-binding oligomerization domain) 1 and
NOD2 are two such receptors. The main outcome of
their engagement with ligand is NF-κB activation, which
almost exclusively occurs via RIP2. Following NOD2
activation, RIP2 mediates Lys63-linked polyubiquitination
of NEMO, which is followed by phosphorylation of IKKβ
and activation of the NF-κB pathway [15].
NEMO is not only polyubiquitinated but also binds
specifically to Lys63-linked polyubiquitin chains via its UBD
[10,16]. It was shown that NEMO binds to polyubiquitinated
RIP2 following TNF stimulation. The UBD was determined
to be the coiled-coil LZ (leucine zipper), which is critical
for TNFα-induced NF-κB activation. A mutation at Lys329,
which is a critical amino acid for ubiquitin binding and
is located in the LZ, is sufficient to block the TNFR1-
mediated recruitment of IKK to TNFR1. In such ways,
NEMO functions as an essential mediator of NF-κB sig-
nalling.
Ubiquitin-mediated activation of NF-κBs
NF-κBs are kept in the cytoplasm in the inactive form in two
ways: bound to their inhibitor IκB or as inactive precursor
proteins. Activation of NF-κB proteins is initiated by the
phosphorylation of their inhibitors by IKK proteins. Fol-
lowing phosphorylation, IκB proteins are polyubiquitinated
via Lys48 and are thus destined for proteasomal degradation.
Ubiquitination of IκB is performed by an E2 ubiquitin-
activating enzyme of the UBC4/5 family followed by E3
ligase action of SCF–βTrCP. There are two different E3
ligases involved in this process, βTrCP1 and βTrCP2, which
have overlapping functions since genetic deletion or silencing
of one of the genes only partially blocks IκBα degradation
[17,18]. The ligases bind only to the phosphorylated form
of the IκBα through their C-terminal part, which allows
the conjugation of ubiquitin to two conserved N-terminal
lysine residues. The ubiquitinated IκBα remains associated
with NF-κB proteins and is selectively degraded in the
proteasome, whereas (non-ubiquitinated) NF-κB is spared
from degradation and released from the inhibitory partner.
Most of the NF-κB precursor proteins such as p105 are
co-translationally processed in a way that depends on the
proteasome only without preceding phosphorylation or
ubiquitination. Also, cell stimulation with LPS (lipopolysac-
charide) can activate the IKK complex that phosphorylates
p105, inducing its processing. On the other hand, processing
of the precursor protein p100 is always dependent on
phosphorylation/ubiquitination. p100 is phosphorylated at a
specific serine residue and polyubiquitinated by SCF–βTrCP,
which induces its proteasomal processing to the mature p52
protein, enabling it to translocate into the nucleus [19]. Both
of the proteins, p100 and p105, are only partially degraded
at their C-terminal part that harbours IκB-like domains. It
is uncertain how the proteasome decides whether to degrade
a protein completely or only partially. In the case of p100
and p105, it seems that ubiquitin tagging of the precursor
proteins attracts the proteasome to the internal, glycine-rich
region where proteolysis starts and proceeds to RHD, which
is difficult to unfold, which makes it difficult to degrade [20].
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Figure 1 Ubiquitin modification in the NF-κB pathway
The classical NF-κB pathway can be triggered by activating several families of cell-surface receptors (TNFR and TLR). Activation
of TNFR results in recruitment of TRADD, TRAF (TRAF-2 or -5) and RIP to the receptor and subsequent Lys63-polyubiquitination
of RIP. Activated RIP stimulates TRAF-6, a ubiquitin E3 ligase and crucial in NF-κB activation. TRAF-6 is also activated via TLR
triggering, through MyD88 and IRAK interaction. TRAF-6 together with TRIKA induces Lys63-polyubiquitination of NEMO and
TRAF-6. Activation of TCR recruits Bcl-10 and MALT1 (mucosa-associated lymphoid tissue lymphoma translocation gene 1)
ubiquitin ligases, which, together with TRAF-6, ligate a Lys63-polyubiquitin chain to NEMO. NEMO activation results in
IKKβ phosphorylation, resulting in proteasomal IκB degradation after phosphorylation and Lys48-polyubiquitination (by
the SCF complex). Now, NF-κB dimers are free to enter the nucleus and activate gene transcription. De-ubiquitination
enzymes, A20 and CYLD, de-ubiquitinate Lys63-chains from target molecules. Also, A20 forms a Lys48-ubiquitin chain on
RIP and therefore can induce its proteasomal degradation. IRF-3, interferon regulatory factor-3; TBK, TANK (TRAF-associated
NF-κB activator)-binding kinase; TRAM, TRIF [TIR (Toll/IL-1 receptor) domain-containing adaptor protein inducing interferon
β]-related adaptor molecule; Ub, ubiquitin.
Negative signalling in the NF-κB pathway
Negative effectors interfere with the strength and the
duration of signalling pathways in a defined window of
time, thereby fine-tuning the signal transmission [21]. In the
NF-κB pathway, transient inhibition of ubiquitin signals is
mediated via the action of DUBs and inhibitory ubiquitin-
binding proteins. To date, two DUBs have been identified to
have important roles in regulating the NF-κB pathway: A20
and CYLD (cylindromatosis) (Figure 1). A20 has a dual role
in down-regulating NF-κB signalling. First, A20 specifically
removes Lys63-linked ubiquitin chains from RIP, an essential
mediator of TNFR1 signalling, and subsequently it attaches
Lys48-linked ubiquitin chains to promote its proteasomal
degradation [22]. CYLD inhibits NF-κB activation by
cleaving Lys63-linked polyubiquitin chains from different
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proteins such as TRAF-2, TRAF-6 and NEMO [23]. Cyld
is a tumour-suppressor gene mutated in familial CYLD, also
called ‘turban tumour syndrome’, an autosomal dominant
predisposition to multiple tumours of the skin appendages
[24]. A recent study showed that CYLD also de-ubiquitinates
the transcriptional co-activator Bcl-3 and prevents its nuclear
translocation where it would collaborate with p50 and p52
proteins. In this way, CYLD action leads to suppression
of transcription of the NF-κB target genes. Moreover,
Cyld-deficient mice had no defect in the transcription
induced by the classical p65–p50 NF-κB dimers, but only
showed excessive NF-κB activation via Bcl-3-linked p50-
or p52-dependent gene regulation, which contributes to the
high sensitivity to skin tumour development in these mice
[25]. Interestingly, a recent report described a new regulatory
role for CYLD in TCR signalling. Cyld-deficient mice are
impaired in thymocyte development due to aberrations in the
transition of double-positive to single-positive T-cells. In
contrast with the finding in keratinocytes, there are no defects
in TNFR-induced NF-κB signalling in BMDMs (bone-
marrow-derived macrophages) of Cyld-deficient mice. The
T-cell phenotype of Cyld-deficient mice resembles the ZAP-
70 [ζ -chain (TCR)-associated protein kinase of 70 kDa]-
deficient thymic phenotype and it was postulated that
CYLD positively regulates TCR signalling in thymocytes by
promoting the recruitment of active Lck to its substrate, ZAP-
70. The role of CYLD in regulation of Lck ubiquitination
and its impact on TCR signalling is unclear at present.
ABIN (A20-binding inhibitor of NF-κB) proteins com-
pose a family of cytosolic proteins (ABIN-1, -2 and -3),
which function in a collaborative manner with A20 to inhibit
NF-κB signalling. ABIN-1 was identified as an interactor of
A20 and binds to the C-terminus of A20 [26]. Moreover, it
was shown that the NF-κB-inhibiting function of A20 can be
mimicked by overexpression of ABIN proteins and may even
be partially mediated through ABIN-1, ABIN-2 and ABIN-
3 [27]. ABIN proteins share a number of conserved regions
termed AHD1–3 (ABIN homology domains 1–3). Interest-
ingly, ABIN was found to possess a UBD that is similar to
the one present in NEMO and Optineurin. Deletion of this
conserved region resulted in the loss of ABIN’s inhibitory
functions [28–30]. Although the ABINs have not yet been
confirmed to be bona fide ubiquitin-binding proteins, the
current indications lead to the exciting possibility that
their ability to bind to ubiquitinated components of the
NF-κB pathway may be central to their role as negative
regulators.
Conclusion
Multiple signalling mechanisms, including allosteric changes,
compartmentalization of activators or effectors and post-
translational modifications, contribute to the regulation
of NF-κB signalling pathways. Among these mechanisms,
ubiquitination acts as a signalling device, fine-tuning and
regulating cellular signalling networks. The complete
knowledge of the signalling interplay between ubiquitination
and other post-translational modifications will have a great
impact on our understanding of biological processes and
contribute to our ability to design novel tools able to
manipulate these processes for therapeutic purposes.
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